This report summarizes the 2022 survey results of the external quality assessment (EQA) scheme for the general transfusion medicine tests and general transfusion antibody test programs in Korea. Proficiency testing materials were prepared at the Asan Medical Center for biannual distribution to participating laboratories. The accuracy rates and number of participating laboratories for the survey items were as follows: ABO typing, 99.4%–99.8% (n=908, n=916); RhD typing, 99.6%–99.9% (n=894, n=902); crossmatching, 82.9%–98.5%; unexpected antibody screening, 99.4%–100.0% (n=343, n=340); direct antiglobulin test (DAT) using a polyspecific reagent, 99.7%– 100.0% (n=293, n=290); DAT using anti-immunoglobulin-G monospecific reagent, 100.0% (n=71, n=72); and DAT using anti-C3d monospecific reagent, 98.6%–100.0% (n=70, n=72). The 2022 EQA scheme for transfusion medicine program has contributed to the program’s improvement and maintenance of the participating laboratories.